BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18977669)

  • 1. The role of salvage treatment in advanced colorectal cancer.
    Capdevila J; Ramos FJ; Macarulla T; Elez E; Tabernero J
    Crit Rev Oncol Hematol; 2009 Jul; 71(1):53-61. PubMed ID: 18977669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic treatment of metastatic colorectal cancer].
    Montemurro M; Achtari L; Röth A; Halkic N; Luthi F; Ozsahin M; Denys A; Bauer J; Demartines N; Leyvraz S
    Rev Med Suisse; 2008 May; 4(158):1254-7. PubMed ID: 18616207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Second-line chemotherapy for colorectal cancer].
    Komatsu Y; Sogabe S; Kawamoto Y; Iwanaga I; Uehata Y; Yuki S; Asaka M
    Gan To Kagaku Ryoho; 2009 May; 36(5):721-5. PubMed ID: 19461170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy.
    Chiappa A; Makuuchi M; Lygidakis NJ; Zbar AP; Chong G; Bertani E; Sitzler PJ; Biffi R; Pace U; Bianchi PP; Contino G; Misitano P; Orsi F; Travaini L; Trifirò G; Zampino MG; Fazio N; Goldhirsch A; Andreoni B
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):65-75. PubMed ID: 19147371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progresses in the medical treatment of advanced colorectal cancer.
    Sultan-Amar V; Fabre-Guillevin E; Piedbois P
    Rocz Akad Med Bialymst; 2005; 50():97-100. PubMed ID: 16358946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
    Benoist S; Nordlinger B
    Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
    Loupakis F; Masi G; Vasile E; Falcone A
    Curr Opin Oncol; 2008 Jul; 20(4):459-65. PubMed ID: 18525344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advance of salvage chemotherapy for colorectal cancer].
    Aiba K; Natori K
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):394-7. PubMed ID: 25963685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line management of metastatic colorectal cancer.
    Gallagher DJ; Kemeny N
    Clin Colorectal Cancer; 2008 Jan; 7(1):25-32. PubMed ID: 18279574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated options for liver-limited metastatic colorectal cancer.
    Alberts SR
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S58-62. PubMed ID: 19064408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on chemotherapy for advanced colorectal cancer.
    Haller DG
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):11-5. PubMed ID: 11301834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line therapy for esophageal cancer.
    Martin MG; Govindan R; Morgensztern D
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):871-6. PubMed ID: 17555397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.
    Braun MS; Quirke P; Seymour MT
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):489-501. PubMed ID: 17428170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent therapy in the palliative treatment of metastatic colorectal cancer.
    Wadhawan A; Stephens R; Adams R
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):125-34. PubMed ID: 19105712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.
    Arkenau HT; Brunetto AT; Barriuso J; Olmos D; Eaton D; de Bono J; Judson I; Kaye S
    Oncology; 2009; 76(3):151-6. PubMed ID: 19169046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.